KALA BIO, Inc. — Director's Dealing 2017

Jul 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2017-07-25

Reporting Person: Hadley Harbor Master Investors (Cayman) L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-07-25	Common Stock	C	888894	—	Acquired	888894	Direct
2017-07-25	Common Stock	C	846566	—	Acquired	846566	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-25	Series B-1 Convertible Preferred Stock	$	C	4629629	Disposed		Common Stock (888894)	Direct
2017-07-25	Series C Convertible Preferred Stock	$	C	4409170	Disposed		Common Stock (846566)	Direct

Footnotes

F1: The Series B-1 Convertible Preferred Stock converted into Common Stock on a 5.2083-for-one basis upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The Series C Convertible Preferred Stock converted into Common Stock on a 5.2083-for-one basis upon the closing of the Issuer's initial public offering. The shares had no expiration date.